{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T01:10:21Z","timestamp":1754183421564,"version":"3.41.2"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Pyoderma gangrenosum (PG) is a rare chronic skin disease characterized by painful skin ulcers. There are no treatment guidelines for PG; however, systemic treatment is often administered. Recently, adalimumab (ADA), a fully human monoclonal antibody against tumour necrosis factor, was approved for the treatment of refractory PG in Japan. However, data are limited, and it is not clear whether ADA has the same effect on the treatment of PG in patients with systemic rheumatic disease (SRD), including rheumatoid arthritis (RA). In addition, the glucocorticoid-sparing effect of ADA in SRD patients with PG has not yet been clarified. Herein, we present two successful cases of RA with glucocorticoid-refractory PG on ADA treatment. Our report suggests that ADA may have a glucocorticoid-sparing effect on refractory PG in patients with RA.<\/jats:p>","DOI":"10.1093\/mrcr\/rxae075","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T15:34:55Z","timestamp":1733412895000},"source":"Crossref","is-referenced-by-count":0,"title":["Glucocorticoid sparing effect on adalimumab for refractory pyoderma gangrenosum in patients with rheumatoid arthritis: A case series"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4149","authenticated-orcid":false,"given":"Shin-ichiro","family":"Ohmura","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Yonezawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Yukishima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Ohkubo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"2025080201014416200_R1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.cpm.2021.06.002","article-title":"Pyoderma gangrenosum: a literature review","volume":"38","author":"Barbe","year":"2021","journal-title":"Clin Podiatr Med Surg"},{"key":"2025080201014416200_R2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2004.07.023","article-title":"Rheumatoid arthritis: a review of the cutaneous manifestations","volume":"53","author":"Sayah","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"2025080201014416200_R3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2249.2010.04201.x","article-title":"Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases","volume":"162","author":"Marzano","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"2025080201014416200_R4","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1080\/003655202320378338","article-title":"Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab","volume":"37","author":"Ljung","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"2025080201014416200_R5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/1346-8138.15533","article-title":"Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: twenty-six-week phase 3 open-label study","volume":"47","author":"Yamasaki","year":"2020","journal-title":"J Dermatol"},{"key":"2025080201014416200_R6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/mrcr\/rxac023","article-title":"Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: a case report and review of the literature","volume":"7","author":"Ohmura","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025080201014416200_R7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archderm.140.7.861","article-title":"Poor prognosis of arthritis-associated pyoderma gangrenosum","volume":"140","author":"Charles","year":"2004","journal-title":"Arch Dermatol"},{"key":"2025080201014416200_R8","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1007\/s10067-021-05768-7","article-title":"Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review","volume":"40","author":"Sawka","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025080201014416200_R9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"2025080201014416200_R10","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaad.2018.10.006","article-title":"Tumor necrosis factor-\u03b1 inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: a multicenter retrospective study","volume":"80","author":"Rousset","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025080201014416200_R11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1346-8138.16337","article-title":"Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52-week phase 3 open-label study","volume":"49","author":"Yamasaki","year":"2022","journal-title":"J Dermatol"},{"author":"Yamamoto","key":"2025080201014416200_R12","article-title":"Committee to Develop a Guide for the Use of Adalimumab in the Treatment of Pyoderma Gangrenosum"},{"key":"2025080201014416200_R13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/ced.12393","article-title":"Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis","volume":"39","author":"Cinotti","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"2025080201014416200_R14","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.jaad.2005.10.058","article-title":"The treatment of pyoderma gangrenosum using etanercept","volume":"54","author":"Roy","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2025080201014416200_R15","doi-asserted-by":"crossref","DOI":"10.1002\/ski2.347","article-title":"Pyoderma gangrenosum-like lesions in the setting of IgA cutaneous vasculitis: Favourable response to adalimumab","volume":"4","author":"Sugino","year":"2024","journal-title":"Skin Health Disease"},{"key":"2025080201014416200_R16","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3109\/s10165-010-0336-0","article-title":"Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis","volume":"20","author":"Tada","year":"2010","journal-title":"Mod Rheumatol"},{"key":"2025080201014416200_R17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00296-017-3861-8","article-title":"Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab","volume":"38","author":"Skalkou","year":"2018","journal-title":"Rheumatol Int"},{"key":"2025080201014416200_R18","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1093\/rheumatology\/keab194","article-title":"Pyoderma gangrenosum induced by adalimumab in a seropositive rheumatoid arthritis patient: a paradoxical effect of adalimumab?","volume":"60","author":"Tan","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025080201014416200_R19","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"2025080201014416200_R20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3109\/14397595.2013.843760","article-title":"Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients","volume":"24","author":"Koike","year":"2014","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxae075\/61201704\/rxae075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxae075\/61201704\/rxae075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxae075\/61201704\/rxae075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:02:24Z","timestamp":1754110944000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxae075\/7919248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxae075","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2024,12,9]]},"article-number":"rxae075"}}